COVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/12511/Elli-Murat-2024.pdf.jpg?sequence=4&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2024Yazar
Bozkurt, CeyhunHazar, Volkan
Malbora, Barış
Küpesiz, Alphan
Aygüneş, Utku
Fışgın, Tunç
Karakükçü, Musa
Kuşkonmaz, Barış
Çakı Kılıç, Suar
Bayırlı, Derya
Arman Bilir, Özlem
Yalçın, Koray
Gözmen, Salih
Uygun, Vedat
Elli, Murat
Sarbay, Hakan
Küpesiz, Funda Tayfun
Şaşmaz, Hatice İlgen
Adaklı Aksoy, Başak
Yılmaz, Ebru
Okur, Fatma Visal
Tekkeşin, Funda
Demir Yenigürbüz, Fatma
Özek, Gülcihan
Atay, Abdullah Avni
Ok Bozkaya, İkbal
Çelen, Suna
Öztürkmen, Seda
Güneş, Adalet Meral
Gürsel, Orhan
Güler, Elif
Özcan, Alper
Uçkan Çetinkaya, Duygu
Aydoğdu, Selime
Özbek, Namık Yaşar
Karasu, Gülsün
Sezgin, Gülay
Doğru, Ömer
Albayrak, Davut
Öztürk, Gülyüz
Aksoylar, Serap
Daloğlu, Hayriye
Odaman Al, Işık
Sezgin Evim, Melike
Akbayram, Sinan
Öncül, Yurday
Zengin, Emine
Albayrak, Canan
Timur, Çetin
Düzenli Kar, Yeter
Çakmaklı, Hasan Fatih
Tüfekçi, Özlem
Töret, Ersin
Antmen, Bülent
Üst veri
Tüm öğe kaydını gösterKünye
Bozkurt, C., Hazar, V., Malbora, B., Küpesiz, A., Aygüneş, U., Fışgın, T. ... Antmen, B. (2024). COVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group. Pediatric Transplantation, 28(3). http://dx.doi.org/10.1111/petr.14758Özet
Background: Data on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited. Objectives: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID-19 infection. Method: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID-19 between March 2020 and August 2022. Results: The median time from HSCT to COVID-19 infection was 209.0 days (IQR, 111.7–340.8; range, 0–3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID-19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p:.001) and lymphopenia at diagnosis (OR, 5.21, p:.006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p:.028), multisystem inflammatory syndrome in children (MIS-C) (OR, 31.07, p:.003), and LRTD (OR, 10.11, p:.035) were associated with a higher risk for COVID-19-related mortality. Conclusion: While COVID-19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS-C or LRTD.
WoS Q Kategorisi
Q4Scopus Q Kategorisi
Q2Kaynak
Pediatric TransplantationCilt
28Sayı
3Koleksiyonlar
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]